Incremental healthcare resource utilization and costs among people living with HIV with and without cardiovascular disease, hypertension, and type 2 diabetes mellitus in the United States
From 2020 through 2022, PLWH with CVD, hypertension, or T2DM experienced a greater HCRU and cost burden than those without these comorbidities. The results highlight the need for individualized HIV care and tailored screening and risk modification interventions for CVD, hypertension, and T2DM.
Authors
- Sean Fleming (ORCID: https://orcid.org/0000-0002-9553-7198)
- Viktor Chirikov (ORCID: https://orcid.org/0000-0002-9480-0580)
- Girish Prajapati
- Mark Bounthavong (ORCID: https://orcid.org/0000-0002-7343-9458)
- Shweta Kamat (ORCID: https://orcid.org/0000-0001-5453-3150)
- Wenying Quan
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- University of California San Diego (US)
- Open Evidence (ES)
- University of Montana (US)
Publication Details
- Journal
- Current Medical Research and Opinion
- Published
- 2025-10-03
- DOI
- https://doi.org/10.1080/03007995.2025.2587401
- Primary Topic
- HIV-related health complications and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00